 Home > Active Ingredient News > Antitumor Therapy > Lancet Oncol: Liposome irinotecan combined with leucovorin and fluorouracil may become the second-line standard treatment for advanced biliary tract cancer!

Lancet Oncol: Liposome irinotecan combined with leucovorin and fluorouracil may become the second-line standard treatment for advanced biliary tract cancer!

 Last Update: 2021-11-02
 Source: Internet
 Author: User

Tags

prezcobix side effects

perfect 5 7

Search more information of high quality chemicals, good prices and reliable suppliers, visit www.echemi.com

The prognosis of advanced biliary tract cancer patients with advanced biliary tract cancer treated with gemcitabine combined with cisplatin is poor
.

This study aimed to evaluate the efficacy and safety of second-line liposomal irinotecan combined with fluorouracil and leucovorin in patients with metastatic biliary cancer who progressed after gemcitabine combined with cisplatin therapy

This is a multicenter, open-label, randomized phase 2b study (NIFTY) that recruited 19-year-old histologically confirmed patients with metastatic biliary tract cancer (ECOG performance status 0 or 1 point)
.

The subjects were randomly (1:1) divided into two groups and received liposomal irinotecan (70 mg/m2) combined with leucovorin (400 mg/m2) and fluorouracil (2400 mg/m2), or leucovorin and fluorouracil , Medication once every two weeks, and stratified according to the primary tumor site, surgical history and center

BICR assessment of progression-free survival

From September 5, 2018 to February 18, 2020, a total of 193 patients underwent eligibility review, of which 174 were recruited into the group: 88 were assigned to the liposomal irinotecan combined with fluorouracil and leucovorin group ( Experimental group), 86 people were divided into fluorouracil and leucovorin group (control group)
.

After a median follow-up of 11.

Side reaction event

The most common grade 3-4 adverse events are neutropenia (experimental group vs control group: 24% vs 1%) and fatigue or weakness (13% vs 3%)
.

In the experimental group and the control group, 37 (42%) and 21 (24%) patients had serious side effects

All in all, adding liposomal irinotecan to the regimen of leucovorin and fluorouracil can significantly prolong the progression-free survival of patients with advanced biliary tract cancer
.

Liposome irinotecan combined with leucovorin and fluorouracil may be used as the standard second-line therapy for patients with advanced biliary tract cancer

The addition of liposomal irinotecan to the regimen of leucovorin and fluorouracil can significantly prolong the progression-free survival of patients with advanced biliary tract cancer

Original source:

Changhoon Yoo, et al.

Liposomal irinotecan plus fluorouracil and leucovorin versus fluorouracil and leucovorin for metastatic biliary tract cancer after progression on gemcitabine plus cisplatin (NIFTY): a multicentre, open-label, randomised, phase 2b study in this message

This article is an English version of an article which is originally in the Chinese language on echemi.com and is provided for information purposes only. This website makes no representation or warranty of any kind, either expressed or implied, as to the accuracy, completeness ownership or reliability of the article or any translations thereof. If you have any concerns or complaints relating to the article, please send an email, providing a detailed description of the concern or complaint, to service@echemi.com. A staff member will contact you within 5 working days. Once verified, infringing content will be removed immediately.